ÂÜÀòÂÒÂ×

Belen Carrillo-Rivas, D.Phil., has a diverse and extensive work experience in the pharmaceutical and biotechnology industries.

Belen currently holds the position of Senior Vice President and Head of Regulatory Affairs at Structure Therapeutics, a role they have held since July 2023.

Prior to this, they were the Senior Vice President and Head of Regulatory Affairs at Imvax, Inc. from June 2022 to May 2023. In this role, they were responsible for developing and executing the regulatory strategy for Imvax's GoldspireTM platform and portfolio across all indications. Belen also played a key role in pioneering regulatory paths and reducing risk for Imvax's innovative cancer immunotherapy platform.

From March 2021 to May 2022, Carrillo-Rivas worked at Saniona as the Vice President and Global Head of Regulatory Affairs. In this position, they focused on developing and executing the company's global regulatory strategy for their medicines, particularly for rare diseases. Belen also worked on enhancing the likelihood of regulatory approval by pursuing novel regulatory pathways and establishing continuous dialogue with regulatory authorities.

Carrillo-Rivas spent a significant part of their career at Pfizer, where they held various roles in Global Regulatory Affairs. Their positions at Pfizer included Head of Global Clinical Submissions Quality from July 2018 to February 2021, Lead for Global Clinical Submissions Quality from December 2015 to July 2018, Lead for Pfizer CURES from February 2015 to December 2015, and Head of R&D Projects & Strategy for the BioTherapeutics R&D Division from February 2010 to January 2015. In these roles, they played a critical role in decision-making regarding regulatory submissions, submission strategy, and clinical data quality. Belen also led the development and execution of key strategic initiatives and programs focused on improving portfolio sustainability, productivity, and pipeline consolidation.

Prior to their time at Pfizer, Carrillo-Rivas held various leadership roles at Resolvyx Pharmaceuticals, Inc., Peptimmune, Daichii Sankyo, Enanta Pharmaceuticals, and Harvard Medical School. In these roles, they gained experience in pharmacology and research, leading programs and projects in the development of pharmaceutical assets.

Overall, Carrillo-Rivas has a wealth of experience in regulatory affairs, strategic leadership, and pharmaceutical development.

Belen Carrillo-Rivas, D.Phil., pursued their doctoral studies in Human/Medical Genetics at the University of Oxford. Belen completed their D.Phil. degree, though the specific dates of their enrollment were not provided. Afterward, from 1997 to 2001, they served as a Postdoctoral Research Fellow in Cellular Immunology at Harvard Medical School. No further information about their educational background is available.